Literature DB >> 15833849

Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-a/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells.

Loïc Vincent1, David K Jin, Matthias A Karajannis, Koji Shido, Andrea T Hooper, William K Rashbaum, Bronislaw Pytowski, Yan Wu, Daniel J Hicklin, Zhenping Zhu, Peter Bohlen, Ruben Niesvizky, Shahin Rafii.   

Abstract

Induction of neoangiogenesis plays an important role in the pathogenesis of multiple myeloma. However, the mechanism by which expression of vascular endothelial growth factor (VEGF)-A and its receptors modulate the interaction of multiple myeloma cells with stromal cells is not known. Here, we describe a novel in vitro coculture system using fetal bone stromal cells as a feeder layer, which facilitates the survival and growth of human primary multiple myeloma cells. We show that stromal-dependent paracrine VEGF-A signaling promotes proliferation of human primary multiple myeloma cells. Primary multiple myeloma cells only expressed functional VEGF receptor (VEGFR)-1, but not VEGFR-2 or VEGFR-3. VEGFR-1 expression was detected in the cytoplasm and the nuclei of proliferating multiple myeloma cells. Inhibition of VEGFR-1 abrogated multiple myeloma cell proliferation and motility, suggesting that the functional interaction of VEGF-A with its cognate receptor is essential for the growth of primary multiple myeloma cells. Collectively, our results suggest that stromal-dependent paracrine and intracrine VEGF-A/VEGFR-1 signaling contributes to human primary multiple myeloma cell growth and therefore, VEGFR-1 blockade is a potential therapeutic strategy for the treatment of multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833849     DOI: 10.1158/0008-5472.CAN-04-3598

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Thirty years of intracrinology.

Authors:  Richard N Re
Journal:  Ochsner J       Date:  2014

2.  VEGF-R1 as a Potential Molecular Target for Anticancer Therapy.

Authors:  E G Tyrsina; S I Nikulitskiy; A N Inshakov; O O Ryabaya
Journal:  Dokl Biochem Biophys       Date:  2018-03-14       Impact factor: 0.788

3.  Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.

Authors:  Patricia M LoRusso; Smitha Krishnamurthi; Hagop Youssoufian; Nancy Hall; Floyd Fox; Aruna Dontabhaktuni; Dmitri Grebennik; Scot Remick
Journal:  Invest New Drugs       Date:  2013-08-01       Impact factor: 3.850

4.  Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma.

Authors:  Bhagavathi A Narayanan; Nicole A Doudican; Jeesun Park; Dazhong Xu; Narayanan K Narayanan; Ramanuj Dasgupta; Amitabha Mazumder
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

5.  Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells.

Authors:  Nader Rahimi; Todd E Golde; Rosana D Meyer
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

6.  Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells.

Authors:  S Samuel; F Fan; L H Dang; L Xia; P Gaur; L M Ellis
Journal:  Oncogene       Date:  2010-11-08       Impact factor: 9.867

7.  VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.

Authors:  Maria Christina Tsourlakis; Puya Khosrawi; Philipp Weigand; Martina Kluth; Claudia Hube-Magg; Sarah Minner; Christina Koop; Markus Graefen; Hans Heinzer; Corinna Wittmer; Guido Sauter; Till Krech; Waldemar Wilczak; Hartwig Huland; Ronald Simon; Thorsten Schlomm; Stefan Steurer
Journal:  Int J Mol Sci       Date:  2015-04-16       Impact factor: 5.923

8.  Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.

Authors:  Tim N Beck; Emmanuelle Nicolas; Meghan C Kopp; Erica A Golemis
Journal:  Oncoscience       Date:  2014-07-23

9.  Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion.

Authors:  Rajat Bhattacharya; Fan Fan; Rui Wang; Xiangcang Ye; Ling Xia; Delphine Boulbes; Lee M Ellis
Journal:  Br J Cancer       Date:  2017-07-25       Impact factor: 7.640

10.  Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1.

Authors:  Tae-Hee Lee; Seyha Seng; Masayuki Sekine; Cimona Hinton; Yigong Fu; Hava Karsenty Avraham; Shalom Avraham
Journal:  PLoS Med       Date:  2007-06       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.